Kiniksa Pharmaceuticals
KNSA
142 hedge funds and large institutions have $628M invested in Kiniksa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 57 reducing their positions, and 20 closing their positions.
54% more call options, than puts
Call options by funds: $7.55M | Put options by funds: $4.91M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
6% more funds holding
Funds holding: 134 → 142 (+8)
2.21% more ownership
Funds ownership: 98.97% → 101.18% (+2.2%)
4% more capital invested
Capital invested by funds: $606M → $628M (+$22.6M)
32% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$27.9M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$6.72M |
| 3 |
Walleye Capital
New York
|
+$5.38M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.09M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$12.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.54M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.29M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.98M |
| 5 |
Millennium Management
New York
|
-$2.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
151
Capula Management
Grand Cayman,
Cayman Islands
| – | -$892K | -51,340 | Closed |
|
|
WG
152
Winton Group
London,
United Kingdom
| – | -$391K | -22,504 | Closed |
|
153
SEI Investments
Oaks,
Pennsylvania
| – | -$362K | -20,819 | Closed |
|
154
Russell Investments Group
London,
United Kingdom
| – | -$363K | -20,814 | Closed |
|
|
NRD
155
Nebula Research & Development
New York
| – | -$238K | -13,686 | Closed |
|
|
EGM
156
Engineers Gate Manager
New York
| – | -$179K | -10,326 | Closed |
|
|
GC
157
Globeflex Capital
San Diego,
California
| – | -$162K | -9,338 | Closed |
|
158
Amundi
Paris,
France
| – | -$94.1K | -5,770 | Closed |
|
|
IA
159
IFP Advisors
Tampa,
Florida
| – | -$65.1K | -3,750 | Closed |
|
160
Lazard Asset Management
New York
| – | -$60K | -3,502 | Closed |
|
|
CSPIA
161
Cary Street Partners Investment Advisory
Richmond,
Virginia
| – | -$17.4K | -1,000 | Closed |
|
162
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$69 | -4 | Closed |
|
KNSA Hedge Fund Activity: Q4 2023 in Review
142 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2023, worth a combined $628M — up 3.7% from $606M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KNSA positions and 20 closed out — a net gain of 9 holders — while 39 added to existing stakes and 57 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $27.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $12.1M sold.
- 142 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2023, up from 134 in Q3 2023.
- Funds reported $628M of Kiniksa Pharmaceuticals stock for Q4 2023, up 3.7% quarter-over-quarter.
- 29 funds opened new Kiniksa Pharmaceuticals positions in Q4 2023 and 20 closed out, a net change of +9 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $27.9M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2023 was HHLR Advisors, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2023.